• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

敏感性分析,以研究使用癌症登记数据时缺失协变量对生存分析的影响。

Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data.

作者信息

Egleston Brian L, Wong Yu-Ning

机构信息

Biostatistics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Stat Med. 2009 May 1;28(10):1498-511. doi: 10.1002/sim.3557.

DOI:10.1002/sim.3557
PMID:19235263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2741403/
Abstract

Having substantial missing data is a common problem in administrative and cancer registry data. We propose a sensitivity analysis to evaluate the impact of a covariate that is potentially missing not at random in survival analyses using Weibull proportional hazards regressions. We apply the method to an investigation of the impact of missing grade on post-surgical mortality outcomes in individuals with metastatic kidney cancer. Data came from the Surveillance Epidemiology and End Results (SEER) registry which provides population-based information on those undergoing cytoreductive nephrectomy. Tumor grade is an important component of risk stratification for patients with both localized and metastatic kidney cancer. Many individuals in SEER with metastatic kidney cancer are missing tumor grade information. We found that surgery was protective, but that the magnitude of the effect depended on assumptions about the relationship of grade with missingness.

摘要

存在大量缺失数据是行政数据和癌症登记数据中的常见问题。我们提出一种敏感性分析方法,以评估在使用威布尔比例风险回归进行的生存分析中,一个可能非随机缺失的协变量的影响。我们将该方法应用于一项关于转移性肾癌患者手术分级缺失对术后死亡率结果影响的调查。数据来自监测、流行病学和最终结果(SEER)登记处,该登记处提供了接受减瘤性肾切除术患者的基于人群的信息。肿瘤分级是局限性和转移性肾癌患者风险分层的重要组成部分。SEER中许多转移性肾癌患者缺失肿瘤分级信息。我们发现手术具有保护作用,但效果的大小取决于关于分级与缺失之间关系的假设。

相似文献

1
Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data.敏感性分析,以研究使用癌症登记数据时缺失协变量对生存分析的影响。
Stat Med. 2009 May 1;28(10):1498-511. doi: 10.1002/sim.3557.
2
Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.淋巴结清扫术的范围并不能提高有淋巴结转移的肾细胞癌患者的生存率:与缺失数据处理相关的偏倚。
BJU Int. 2014 Jan;113(1):36-42. doi: 10.1111/j.1464-410X.2012.11693.x. Epub 2013 Mar 12.
3
Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.转移性非透明细胞肾细胞癌患者细胞减灭性肾切除术后的生存情况:一项基于人群的研究。
Eur Urol Focus. 2019 May;5(3):488-496. doi: 10.1016/j.euf.2017.11.012. Epub 2017 Dec 8.
4
Implications of missing data on reported breast cancer mortality.报告乳腺癌死亡率数据缺失的影响。
Breast Cancer Res Treat. 2023 Jan;197(1):177-187. doi: 10.1007/s10549-022-06764-4. Epub 2022 Nov 5.
5
Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.转移性透明细胞肾细胞癌患者根治性细胞减灭性肾切除术后与未手术患者生存率的评估:一项监测、流行病学和最终结果(SEER)分析
Int Braz J Urol. 2015 Mar-Apr;41(2):288-95. doi: 10.1590/S1677-5538.IBJU.2015.02.15.
6
Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.原发肿瘤大小对接受细胞减灭性肾切除术的转移性肾细胞癌患者预后的影响:中国中心和美国 SEER 数据库的人群研究。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211019507. doi: 10.1177/15330338211019507.
7
Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.在肾切除术中,淋巴结受累与生存率较差相关:分期和分级分析。
Int J Urol. 2013 Apr;20(4):372-80. doi: 10.1111/j.1442-2042.2012.03170.x. Epub 2012 Oct 8.
8
Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry.从国家癌症登记处比较早期肾癌微创与开放手术切除后的癌症特异性结局。
J Urol. 2020 Jun;203(6):1094-1100. doi: 10.1097/JU.0000000000000741. Epub 2020 Jan 8.
9
Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.减瘤性部分肾切除术不会削弱转移性肾细胞癌的癌症控制效果:一项基于人群的研究。
Urology. 2008 Nov;72(5):1090-5. doi: 10.1016/j.urology.2008.06.059. Epub 2008 Sep 16.
10
Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.围手术期感染对肾癌肾切除术患者癌症特异性生存的影响。
J Urol. 2017 Nov;198(5):1027-1032. doi: 10.1016/j.juro.2017.05.070. Epub 2017 May 25.

引用本文的文献

1
Implications of missing data on reported breast cancer mortality.报告乳腺癌死亡率数据缺失的影响。
Breast Cancer Res Treat. 2023 Jan;197(1):177-187. doi: 10.1007/s10549-022-06764-4. Epub 2022 Nov 5.
2
Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database.在初治及曾用唑来膦酸预处理组中,地诺单抗所致颌骨坏死:一项使用日本药品不良事件报告(JADER)数据库的发病时间研究。
Drugs Real World Outcomes. 2022 Dec;9(4):659-665. doi: 10.1007/s40801-022-00324-4. Epub 2022 Aug 6.
3
Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival.国家癌症数据库中数据缺失的发生率及其与总生存的关系。
JAMA Netw Open. 2021 Mar 1;4(3):e211793. doi: 10.1001/jamanetworkopen.2021.1793.
4
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.利用综合列线图评估局限性肾细胞癌患者的总生存和死亡竞争风险。
J Clin Oncol. 2010 Jan 10;28(2):311-7. doi: 10.1200/JCO.2009.22.4816. Epub 2009 Nov 23.

本文引用的文献

1
Disparities in treatment and outcome for renal cell cancer among older black and white patients.老年黑人和白人患者肾细胞癌治疗及预后的差异
J Clin Oncol. 2007 Aug 20;25(24):3589-95. doi: 10.1200/JCO.2006.10.0156.
2
Prognostic ability of simplified nuclear grading of renal cell carcinoma.肾细胞癌简化核分级的预后能力
Cancer. 2007 Mar 1;109(5):868-74. doi: 10.1002/cncr.22463.
3
Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?转移性肾细胞癌的减瘤性肾切除术:在靶向治疗时代它仍然必不可少吗?
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):693s-696s. doi: 10.1158/1078-0432.CCR-06-1916.
4
Sorafenib in advanced clear-cell renal-cell carcinoma.索拉非尼治疗晚期透明细胞肾细胞癌
N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655.
5
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
6
Survival associated with treatment vs observation of localized prostate cancer in elderly men.老年男性局限性前列腺癌治疗与观察的生存情况比较
JAMA. 2006 Dec 13;296(22):2683-93. doi: 10.1001/jama.296.22.2683.
7
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.转移性肾细胞癌患者的治疗:一个兰德适宜性专家组。
Cancer. 2006 Nov 15;107(10):2375-83. doi: 10.1002/cncr.22260.
8
Identifiability assumptions for missing covariate data in failure time regression models.失效时间回归模型中缺失协变量数据的可识别性假设
Biostatistics. 2007 Apr;8(2):345-56. doi: 10.1093/biostatistics/kxl014. Epub 2006 Jul 13.
9
Risk of fracture after androgen deprivation for prostate cancer.前列腺癌雄激素剥夺治疗后的骨折风险。
N Engl J Med. 2005 Jan 13;352(2):154-64. doi: 10.1056/NEJMoa041943.
10
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.使用加利福尼亚大学洛杉矶分校综合分期系统预测肾细胞癌的生存率:一项国际多中心研究。
J Clin Oncol. 2004 Aug 15;22(16):3316-22. doi: 10.1200/JCO.2004.09.104.